Boston Scientific Corp. (NASDAQ: BSX) director Susan E. Morano purchased 2,040 common shares on August 25 for a total of $100,407, according to a Securities and Exchange Commission filing.
The transaction was executed at an average price of $49.2195 per share, approximately 2.2% above the $48.17 closing price on August 26, when the filing was disclosed. Following the purchase, Morano’s direct shareholding in the company rose to 13,784 shares.
The medical device maker, valued at $72.3 billion, has recently faced operational challenges. Boston Scientific reported a cybersecurity incident disrupting global information systems, which temporarily impaired order processing and shipping capabilities. The company engaged third-party experts to investigate and mitigate the breach.
Analysts offered mixed assessments of Boston Scientific’s outlook. Stifel maintained a "buy" rating with a $60 price target, while TD Cowen reiterated its "buy" rating with a $56 target. Argus, however, downgraded the stock to "neutral," citing growth headwinds in key product segments including WATCHMAN, electrophysiology, and urology. Boston Scientific’s shares trade at a price-to-earnings ratio of 19.62 and a PEG ratio of 0.4, with InvestingPro noting a valuation below short-term earnings growth expectations.
